Bioequivalence and Bioavailability Forum

Thanks for all who gave me a great reply.,

The analysis model which i have taken:

Group, sequence, sequence*group, period*group, formulation and formulation*group interaction as fixed effects and subject nested within group*sequence as a random effect. Sequence, sequence*group and group were tested using the Type III mean-square term for subject nested within sequence*group as the error term, at a 10% level of significance.

The formulation, period*group and formulation*group effects were tested against the residual mean square error. Probability (p) values were derived from Type III sums of squares with 5% level of significance.

In this model which significant effects i should consider…

And If i get formulation*group interaction was statistically significant for one PK parameter so, what is the next step i have to take in this…? Will it effect on the BE criteria...?


Thanks in advance…

Sangeea